nach oben

Reviews in Endocrine and Metabolic Disorders

Erschienen in:

01.09.2014

Effects of GLP-1 on appetite and weight

verfasst von: Meera Shah, Adrian Vella

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Glucagon-like peptide 1 (GLP-1) is a cleavage product of the pre-proglucagon gene which is expressed in the α-cells of the pancreas, the L-cells of the intestine, and neurons located in the caudal brainstem and hypothalamus. GLP-1 is of relevance to appetite and weight maintenance because it has actions on the gastrointestinal tract as well as the direct regulation of appetite. It delays gastric emptying and gut motility in humans. In addition, interventricular injections of GLP-1 inhibit food intake, independent of the presence of food in the stomach or gastric emptying. Peripherally administered GLP-1 also affects the central regulation of feeding. It is therefore the synergistic actions of GLP-1 in the gut and brain, acting on both central and peripheral receptors that seem responsible for the effects of the hormone on satiety.

Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409–39.PubMedCrossRef

Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131–57.PubMedCrossRef

Dailey MJ et al. Disassociation between preprandial gut peptide release and food-anticipatory activity. Endocrinology. 2012;153:132–42.PubMedCentralPubMedCrossRef

Vahl TP et al. Meal-anticipatory glucagon-like peptide-1 secretion in rats. Endocrinology. 2010;151:569–75.PubMedCentralPubMedCrossRef

Tang-Christensen M, Vrang N, Larsen PJ. Glucagon-like peptide containing pathways in the regulation of feeding behaviour. Int J Obes Relat Metab Disord. 2001;25 Suppl 5:S42–7.PubMedCrossRef

Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J. Glucagon-like peptide-1 (7–36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol. 1993;138:159–66.PubMedCrossRef

Hermann C, Goke R, Richter G, Fehmann HC, Arnold R, Goke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion. 1995;56:117–26.CrossRef

Rocca AS, Brubaker PL. Role of the vagus nerve in mediating proximal nutrient-induced glucagon- like peptide-1 secretion. Endocrinology. 1999;140(4):1687–94.PubMed

Balks HJ, Holst JJ, Von Zur MA, Brabant G. Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: Cholinergic control of GLP-1 secretion via muscarinic receptors. J Clin Endocrinol Metab. 1997;82(3):786–90.PubMed

10.

Theodorakis MJ, Carlson O, Michopoulos S, et al. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab. 2006;290:E550–9.PubMedCrossRef

11.

Tolhurst G, Reimann F, Gribble FM. Nutritional regulation of glucagon-like peptide-1 secretion. J Physiol. 2009;587(1):27–32.PubMedCentralPubMedCrossRef

12.

Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Oxyntomodulin from distal gut: role in regulation of gastric and pancreatic functions. Dig Dis Sci. 1989;34:1411–9.PubMedCrossRef

13.

Tang-Christensen M, Larsen PJ, Thulesen J, Rømer J, Vrang N. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med. 2000;6(7):802–7.PubMedCrossRef

14.

Lovshin J, Estall J, Yusta B, Brown TJ, Drucker DJ. Glucagon-like Peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling. J Biol Chem. 2001;276(24):21489–99.PubMedCrossRef

15.

Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273:E981–8.PubMed

16.

Schirra J, Wank U, Arnold R, Goke B, Katschinski M. Effects of glucagon-like peptide-1 (7–36) amide on motility and sensation of the proximal stomach in humans. Gut. 2002;50:341–8.PubMedCentralPubMedCrossRef

17.

Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2003;88:2719–25.PubMedCrossRef

18.

Delgado-Aros S, Doe-Young K, Burton DD, Thomforde GM, et al. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol. 2002;282:G424–31.PubMed

19.

Ruttimann EB et al. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology. 2009;150:1174–81.PubMedCentralPubMedCrossRef

20.

Turton MD, O’Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996;379:69–72.PubMedCrossRef

21.

Barrera JG et al. Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function. J Neurosci. 2011;31:3904–13.PubMedCentralPubMedCrossRef

22.

Chaudhri OB, Parkinson JR, Kuo YT, et al. Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging. Biochem Biophys Res Commun. 2006;350:298–306.PubMedCrossRef

23.

Min DK, Tuor UI, Koopmans HS, Chelikani PK. Changes in differential functional magnetic resonance signals in the rodent brain elicited by mixed-nutrient or protein-enriched meals. Gastroenterology. 2011;141:1832–41.PubMedCrossRef

24.

Dailey M.J., Moran T. H. Glucagon-like peptide 1 and appetite. Trends in Endocrinology and Metabolism. 2013; 24 (2).

25.

Larsen PJ et al. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology. 1997;138:4445–55.PubMed

26.

Seo S. Acute effects of glucagon-like peptide-1 on hypothalamic neuropeptide and AMP activated kinase expression in fasted rats. Endocr J. 2008;55:867–74.PubMedCrossRef

27.

Bugarith K et al. Basomedial hypothalamic injections of neuropeptide Y conjugated to saporin selectively disrupt hypothalamic controls of food intake. Endocrinology. 2005;146:1179–91.PubMedCrossRef

28.

Blevins JE, Baskin DG. Hypothalamic-brainstem circuits controlling eating. Forum Nutr. 2010;63:133–40.PubMedCrossRef

29.

Richards P, Parker HE, Adriaenssens AE, et al. (2013) Identification and characterisation of glucagon-like peptide-1 receptor expressing cells using a new transgenic mouse model. Diabetes; Publish Ahead of Print, published online December 2, 2013.

30.

Kinzig KP et al. The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neurosci. 2002;22:10470–6.PubMed

31.

Dailey MJ, Moran T. H. Glucagon-like peptide 1 and appetite. Trends in Endocrinology and Metabolism. 2013;24 (2).

32.

Kellum JM, Kuemmerle JF, O’Dorisio TM. Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty. Ann Surg. 1990;211:763–70.PubMedCentralPubMedCrossRef

33.

Laferrère B, Teixeira JMJ. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:2479–85.PubMedCentralPubMedCrossRef

34.

le Roux CW, Aylwin SJ, Batterham RL. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006;243:108–14.PubMedCentralPubMedCrossRef

35.

Kashyap SR, Bhatt DL, Wolski K. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care. 2013;36:2175–82.PubMedCentralPubMedCrossRef

36.

Gagner M. Sleeve gastrectomy: an ideal choice for T2DM. Nat Rev Endocrinol. 2013;9:623.PubMedCrossRef

37.

Habegger KM, Kirchner H, Yi CX, Heppner KM, et al. GLP-1R agonism enhances adjustable gastric banding in diet-induced obese rats. Diabetes Care. 2013;62(9):3261–7.CrossRef

38.

Shah M, Law JH, Micheletto F, et al. Contribution of endogenous glucagon-like peptide-1 to glucose metabolism after Roux-en-Y gastric bypass. Diabetes. 2014;63:1–10.CrossRef

39.

Deane AM, Nguyen NQ, Stevens JE. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab. 2010;95:215–21.PubMedCrossRef

40.

Nicolaus M, Brödl J, Linke R, Woerle H-J, Göke B, Schirra J. Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying. J Clin Endocrinol Metab. 2011;96:229–36.PubMedCrossRef

41.

Wilson-Perez HE, Chambers AP, Ryan KK, Li B, Sandoval DA, et al. Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like peptide 1 receptor deficiency. Diabetes. 2013;62(7):2380–5.PubMedCentralPubMedCrossRef

42.

Nea I. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol Rev. 1997;273:G920–7.

43.

Aea W. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol. 1998;275:G984–92.

44.

Aea A. Peripheral motor action of glucagon-like peptide-1 through enteric neuronal receptors. Neurogastroenterol Motil. 2010;22:664–e203.CrossRef

45.

Mea T-C. Central administration of GLP-1-(7–36) amide inhibits food and water intake in rats. Am J Physiol. 1996;271:R848–56.

46.

Gulpinar MA. Glucagon-like peptide (GLP-1) is involved in the central modulation of fecal output in rats. Am J Physiol Gastrointest Liver Physiol. 2000;278:924–9.

47.

Ayachi SE. Contraction induced by glicentin on smooth muscle cells from the human colon is abolished by exendin (9–39). Neurogastroenterol Motil. 2005;17:302–9.PubMedCrossRef

48.

Yoder SM. Stimulation of incretin secretion by dietary lipid: is it dose dependent? Am J Physiol Gastrointest Liver Physiol. 2009;297:299–305.CrossRef

49.

Wank U, Schirra J, Arnold R, Goke B, Katschinki M. Effects of GLP-1 on proximal gastric motor and sensory function in human. Gastroenterology. 1998;114:A1190.CrossRef

50.

Delgado-Aros S, Vella A, Camilleri M, et al. Effects of glucagon-like peptide-1 and feeding on gastric volumes in diabetes mellitus with cardio-vagal dysfunction. Neurogastroenterol Motil. 2003;15:435–43.PubMedCrossRef

51.

Holst JJ, Toft-Nielsen MB, Orskov C, Nauck M, Willms B. On the effects of glucagon-like peptide-1 on blood glucose regulation in normal and diabetic subjects. Ann N Y Acad Sci. 1996;805:729–36.PubMedCrossRef

52.

Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a arallel-group study. Lancet. 2002;359:824–30.PubMedCrossRef

53.

Vilsboll T, Christensen M, Junker AE FKK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:7771.CrossRef

54.

Buse JB, Henry RR, Han J, Kim DD, MS F, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628–35.PubMedCrossRef

55.

DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092–100.PubMedCrossRef

56.

Moretto TJ, Milton DR RT, Macconell LA, Okerson T, AM W, Brodows RG. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group study. Clin Ther. 2008;30:1448–60.PubMedCrossRef

57.

Astrup A, Rossner S, Van GL, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606–16.PubMedCrossRef

58.

Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Curr Med Res Opin. 2009;25:65–75.PubMedCrossRef

59.

Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia. 2009;52:2046–55.PubMedCentralPubMedCrossRef

60.

Gallwitz B, Bohmer M, Segiet T, et al. Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia. Diabetes Care. 2011;34:604–6.PubMedCentralPubMedCrossRef

61.

Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39–47.PubMedCrossRef

62.

Buse JB, Nauck M, Forst T. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381:117–24.PubMedCrossRef

63.

Kelly A, Rudser KD, Nathan BM, Fox CK, et al. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity. JAMA Pediatr. 2013;167(4):355–60.PubMedCentralPubMedCrossRef

64.

Bunck MC, Diamant M, Eliasson B, et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care. 2010;33:1734–7.PubMedCentralPubMedCrossRef

65.

Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009;11:1163–72.PubMedCrossRef

66.

Zoicas F, Droste M, Mayr B, Buchfelder M, Schofl C, et al. GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases. Eur J Endocrinol. 2013;168(5):699–706.PubMedCrossRef

67.

Garber A, Henry RR RR, Hale P, CT C, Bode B. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13:348–56.PubMedCentralPubMedCrossRef

68.

Macconell L, Pencek R, Li Y, Maggs D, Porter L. Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. Diabetes Metab Syndr Obes. 2013;6:31–41.PubMedCentralPubMed

69.

Bunck MC, Corner A, Eiasson B, et al. Effects of exenatide on measures of beta-cell function after 3years in metformin-treated patients with type 2 diabetes. Diabetes Care. 2011;34:2041–7.PubMedCentralPubMedCrossRef

70.

van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M. Effects of GLP-1 on appetite and body weight: focus on the central nervous system. J Endocrinol. 2013 (Dec 9. [Epub ahead of print]).

71.

Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013;62:2595–604.PubMedCentralPubMedCrossRef

72.

Kral JG. Vagal nerve function in obesity: therapeutic implications. World J Surg. 2009;33:1995–2006.PubMedCrossRef

73.

Hoyda TD, Smoth PM, Ferguson AV. Gastrointestinal hormone actions in the central regulation of energy metabolism: potential sensory roles for the circumventricular organs. Int J Obes. 2009;33:S16–21.CrossRef

74.

Thorens B, Larsen P. Gut-derived signaling molecules and vagal afferents in the control of glucose and energy homeostasis. Curr Opin Clin Nutr Metab Care. 2004;7:471–8.PubMedCrossRef

Titel: Effects of GLP-1 on appetite and weight
verfasst von: Meera Shah
Adrian Vella
Publikationsdatum: 01.09.2014
Verlag: Springer US
Erschienen in: Reviews in Endocrine and Metabolic Disorders / Ausgabe 3/2014
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-014-9289-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Effects of GLP-1 on appetite and weight

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

Gut microbiota and GLP-1

Extrapancreatic effects of GLP-1 and other incretins

Cardiovascular and hemodynamic effects of glucagon-like peptide-1

Effects of GLP-1 in the Kidney

GLP-1R activation for the treatment of stroke: Updating and future perspectives

Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin